Australia markets open in 2 hours 25 minutes

AVXL Jan 2023 15.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
2.9400+0.6500 (+28.38%)
As of 10:36AM EDT. Market open.
Full screen
Previous close2.2900
Open3.0000
Bid2.6500
Ask3.4000
Strike15.00
Expiry date2023-01-20
Day's range2.9400 - 3.0000
Contract rangeN/A
Volume2
Open interest731
  • Zacks

    Celldex (CLDX) Initiates Phase II Chronic Skin Disorder Study

    Celldex (CLDX) initiates dosing in a mid-stage study designed to evaluate its antibody candidate, barzolvolimab, for treating patients with chronic spontaneous urticaria.

  • GlobeNewswire

    Anavex Life Sciences Announces Its Very First Scientific Educational Video News Release

    NEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, today announces Anavex’s very first Educational Video News Release, which can be accessed via Anavex's newsroom. To

  • Zacks

    How Much Upside is Left in Anavex Life Sciences (AVXL)? Wall Street Analysts Think 286%

    The average of price targets set by Wall Street analysts indicates a potential upside of 286.4% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.